Wockhardt has received approval from the United States Food & Drug Administration (USFDA) for an ANDA for 1gm, and 2gm injections of Oxacillin. The pharma major is expected to launch this product in the United States, soon. The product is being manufactured at a contract manufacturing facility, based near Milan, Italy.
Oxacillin is a penicillanase-resistant beta-lactam antibiotic and is used to treat many different infections caused by penicillin-resistant Staphylococcal and other bacterial infections, such as Urinary Tract Infections, Respiratory Tract Infections, Septicemia, Wound Infection, Bacterial meningitis etc.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
